326914-06-1

Basic information

• Product Name: MHY1485
• Synonyms: MHY1485;4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine;4,6-Di-4-morpholinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
• CAS NO: 326914-06-1
• Molecular Formula: C17H21N7O4
• Molecular Weight: 387.39314
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 326914-06-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 256-259 °C
• Boiling Point: 643.3±65.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.415±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble2mg/mL, clear (warmed)
• PKA: 6.19±0.10(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: MHY1485(CAS DataBase Reference)
• NIST Chemistry Reference: MHY1485(326914-06-1)
• EPA Substance Registry System: MHY1485(326914-06-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 326914-06-1(Hazardous Substances Data)

Usage

Description

MHY1485 is a cell-permeable activator of mTOR, a serine/threonine protein kinase that plays a crucial role in regulating cell growth, proliferation, and survival. It has been shown to increase levels of cellular mTOR Ser2448 and downstream substrate 4E-BP Thr37/46 phosphorylation in rat liver Ac2F cells. MHY1485 can also induce cellular LC3-II accumulation in Ac2F cells and has been shown to inhibit autophagy by suppressing the fusion between autophagosomes and lysosomes.

Uses

Used in Pharmaceutical Research:
MHY1485 is used as a research tool for studying the effect of mammalian target of rapamycin (mTOR) signaling on in vitro O-GlcNAcylation. It helps in understanding the role of mTOR in various cellular processes and its potential as a therapeutic target for various diseases.
Used in Cancer Research:
MHY1485 is used as an mTOR agonist to demonstrate that the O-linked N-acetylglucosamine transferase-RNA helicase p68 (OGT-DDX5) axis regulates colorectal cancer cell proliferation and metastasis. This finding could potentially lead to the development of new therapeutic strategies for the treatment of colorectal cancer.
Used in Autophagy Research:
MHY1485 is used to inhibit autophagy, a cellular process that helps in the degradation and recycling of cellular components. By suppressing the fusion between autophagosomes and lysosomes, MHY1485 provides insights into the regulation of autophagy and its role in various diseases, including cancer and neurodegenerative disorders.

Biochem/physiol Actions

MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.

References

1) Choy et al. (2012), Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion; PLoS One, 7(8) e43418 2) Cheng et al. (2015), Promotion of ovarian follicle growth following mTOR activation: synergistic effects of AKT stimulators; PLoS One, 10(2) e0117769 3) Zhao et al. (2016), MHY1485 activates mTOR and protects osteoblasts from dexamethasone; Biochem. Biophys. Res. Commun., 481 212 4) Yang et al. (2017), MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling; Oncotarget, 8 12775 5) Li and Siragy (2015), (Pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose; J. Physiol. Endocrinol. Metab., 309 E302

Upstream product

• 110-91-8 morpholine 
• 2352-36-5 4,6-dichloro-N-(4-nitrophenyl)-1,3,5-triazin-2-amine 
• 100-01-6 4-nitro-aniline 
• 7597-22-0 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine 

Relevant articles and documents

Investigations of antiproliferative and antioxidant activity of β-lactam morpholino-1,3,5-triazine hybrids

This article reports for the first time the synthesis of some novel β-lactam morpholino-1,3,5-triazine hybrids by a [2+2]-cycloaddition reaction of imines 7a–c, 9a–c and 11 with ketenes derived from substituted acetic acids. The reaction was totally diastereoselective, leading exclusively to the formation of cis-β-lactams 8a–l, 10a–f and 12a–c. The synthesized compounds were tested for activity towards SW1116, MCF-7 and HepG2 cancer cell lines and non-cancerous HEK-293 cell line by MTT assay. None of the compounds exert an observable effect on HepG2, MCF-7 and HEK-293 cells, but compounds 7b, 8f, 8g, 8l, 10c, and 10e exhibited excellent growth inhibitory activity (IC50 50 = 6.9 μM). An evaluation of the antioxidant potential of each of the compounds, performed by diphenylpicrylhydrazyl (DPPH) assay, indicated that 7b, 9a, 9b and 9c have strong free radical scavenging activity. UV absorption titration studies reveal that 7b, 8l, 8g and 8f interact strongly with calf-thymus DNA (CT-DNA) in the order of 8l > 7b > 8f > 8g. Collectively, the in vitro capabilities of some of these morpholino-triazine imines and β-lactams suggest possible applications to development of new antioxidants and DNA binding therapeutics.

Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents

A series of 2,4,6-trisubstituted-1,3,5-triazines (2a-s) were synthesized and evaluated for their in vitro antimalarial activity against P. falciparum. Out of the 19 compounds synthesized eight compounds showed MIC in the range of 1-2 μg/mL. These compounds are in vitro several times more active than cycloguanil.